High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia.
Africa
HBV functional cure
HIV-HBV coinfection
antiretroviral therapy outcomes
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
02 01 2020
02 01 2020
Historique:
received:
01
06
2019
accepted:
30
08
2019
pubmed:
16
10
2019
medline:
2
10
2020
entrez:
16
10
2019
Statut:
ppublish
Résumé
Among 284 human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenofovir-based antiretroviral therapy (ART) in Zambia, median baseline CD4+ count was 202 cells/mm3 and 41.6% were hepatitis B e-antigen positive. Within 2 years of therapy, 29 (10.2%) participants experienced HBV functional cure (confirmed loss of hepatitis B surface antigen). In multivariable analysis, baseline CD4 count <350 cells/mm3, female sex, and lower baseline HBV deoxyribonucleic acid were associated with increased odds of functional cure. Immune recovery during HIV-HBV treatment with ART may drive higher rates of functional cure than during HBV monoinfection treatment. Understanding the mechanisms underlying this phenomenon could inform immunomodulatory therapies for HBV cure.
Identifiants
pubmed: 31613956
pii: 5581876
doi: 10.1093/infdis/jiz450
pmc: PMC7184905
doi:
Substances chimiques
Anti-Retroviral Agents
0
Tenofovir
99YXE507IL
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
218-222Subventions
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States
Organisme : FIC NIH HHS
ID : K01 TW009998
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Clin Infect Dis. 2018 Jan 6;66(1):112-120
pubmed: 29020361
Clin Infect Dis. 2017 May 15;64(10):1343-1349
pubmed: 28158504
AIDS Behav. 2018 Jul;22(7):2334-2339
pubmed: 29336004
J Virol. 2005 Mar;79(5):3038-51
pubmed: 15709024
Gut. 2014 Aug;63(8):1325-32
pubmed: 24162593
Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):337-345
pubmed: 28774416
Gastroenterol Hepatol (N Y). 2017 Jun;13(6):348-356
pubmed: 28690451
Gastroenterology. 2019 Feb;156(3):635-646.e9
pubmed: 30342034
AIDS. 2017 Sep 24;31(15):2035-2052
pubmed: 28692539
PLoS One. 2013 Apr 09;8(4):e61297
pubmed: 23593455
J Gastroenterol Hepatol. 2016 Mar;31(3):634-44
pubmed: 26313291
Open Forum Infect Dis. 2016 Aug 16;3(3):ofw140
pubmed: 27800524
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82
pubmed: 23892239
J Infect Dis. 2012 Sep 15;206(6):974-80
pubmed: 22782950